Drugs / CD 133+ bone marrow stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02870933 | Jan 2016 → Apr 2018 | coronary artery disorder | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD 133+ bone marrow stem cells | “In this study, we use CD 133+ bone marrow stem cells which has been proved to have higher angiogenesis potential.” NCT02870933 ↗ |
| Modality | Cell therapy | “In this study, we use CD 133+ bone marrow stem cells which has been proved to have higher angiogenesis potential.” NCT02870933 ↗ |
| Route | Other | “The stem cells is given during CABG by injection transepicardial and transseptal.” NCT02870933 ↗ |